Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Go back to Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)| (NASDAQ: SRRK) | Delayed: 46.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.65 | 52 Week High | $ | |||
| Open | $46.65 | 52 Week Low | $ | |||
| Day High | $46.65 | P/E | N/A | |||
| Day Low | $46.65 | EPS | $ | |||
| Volume | 229 | |||||
